Received Mar 20, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (PRIORIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 7HG2A | — |
patient that received it was born in 1957; administration via intramuscular; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of inappropriate age at vaccine administration in a 67-year-old female patient who received MMR (Priorix) (batch number 7HG2A, expiry date 01-JAN-2026) for prophylaxis. On 10-MAR-2025, the patient received Priorix. On 10-MAR-2025, an unknown time after receiving Priorix, the patient experienced inappropriate age at vaccine administration (Verbatim: patient that received it was born in 1957) and subcutaneous injection formulation administered by other route (Verbatim: administration via intramuscular). The outcome of the inappropriate age at vaccine administration and subcutaneous injection formulation administered by other route were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 11-MAR-2025 Pharmacist wanted to know if the administration via intramuscular of Priorix in a patient was correct or not, but also mention that the patient that received it was born in X. Patient received the vaccine via intramuscular route at the age of 67 years, which led to subcutaneous injection formulation administered by other route and inappropriate age at vaccination.